• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Ginsenoside Rg1

Ginsenoside Rg1

Product ID G3458
Cas No. 22427-39-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $93.80 In stock
5 mg $260.00 In stock
10 mg $439.40 In stock
25 mg $859.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Ginsenoside Rg1 is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-inflammatory, neuroprotective, anti-aging, anti-fibrotic, anticancer, antithrombotic, anti-allergic, immunomodulatory, cardioprotective, and pro-angiogenic activities. In an animal model of aging, ginsenoside Rg1 prevents decreases in cognitive capacity and neurogenesis, and suppresses astrocyte activation and production of TNF-α, IL-6, and IL-1β; it also increases activity of telomerase, glutathione peroxidase, and superoxide dismutase. In other animal models, ginsenoside Rg1 decreases levels of ALT, AST, LDH, and ALP, inhibiting inflammation and hepatic stellate cell activation, decreasing fibrosis. Additionally, ginsenoside Rg1 suppresses JAK2/STAT5 signaling in leukemia cells, upregulates expression of Bax and caspase 3, downregulates expression of Bcl-2, induces apoptosis, and inhibits cell proliferation. This compound also inhibits platelet aggregation, fibrinogen binding, P-selection expression, platelet adhesion, and ERK activation, increasing time to occlusion in vivo. Ginsenoside Rg1 inhibits left ventricular hypertrophy and increases expression of HIF-1α and VEGF in other animal models. This compound also decreases serum histamine, IgE, and IgG and suppresses infiltration of eosinophils and mast cells in animal models of allergic rhinitis.

Product Info

Cas No.

22427-39-0

Purity

≥98%

Formula

C42H72O14

Formula Wt.

801.01

IUPAC Name

(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3, 12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S, 6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3, 5,6,7,9,11,12,13,15,16, 17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl) oxane-3,4,5-triol

Synonym

Sanchinoside Rg1, Panaxoside A

Melting Point

194-196.5 ℃

Appearance

White Powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

G3458 MSDS PDF

Info Sheet

G3458 Info Sheet PDF

References

Lin L, Chen D, Li S, et al. Ginsenoside Rg1 inhibits multiple myeloma and overcomes bortezomib resistance through AMPK-mTOR pathway. Heliyon. 2024 Jul 1;10(13):e33935. PMID: 39071579.

Zhu J, Mu X, Zeng J, et al. Ginsenoside rg1 prevents cognitive impairment and hippocampus senescence in a rat model of d-galactose-induced aging. PLoS One. 2014 Jun 30;9(6):e101291. PMID: 24979747.

Li JP, Gao Y, Chu SF, et al. Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl4-induced hepatic fibrosis. Acta Pharmacol Sin. 2014 Jun 30. [Epub ahead of print]. PMID: 24976156.

Li J, Wei Q, Zuo GW, et al. Ginsenoside Rg1 induces apoptosis through inhibition of the EpoR-mediated JAK2/STAT5 signalling pathway in the TF-1/ Epo human leukemia cell line. Asian Pac J Cancer Prev. 2014;15(6):2453-9. PMID: 24761846.

Zhou Y, Li HQ, Lu L, et al. Ginsenoside Rg1 provides neuroprotection against blood brain barrier disruption and neurological injury in a rat model of cerebral ischemia/reperfusion through downregulation of aquaporin 4 expression. Phytomedicine. 2014 Jun 15;21(7):998-1003. PMID: 24462216.

He Y, Zhao H, Su G. Ginsenoside Rg1 decreases neurofibrillary tangles accumulation in retina by regulating activities of neprilysin and PKA in retinal cells of AD mice model. J Mol Neurosci. 2014 Jan;52(1):101-6. PMID: 24287922.

Zhou Q, Jiang L, Xu C, et al. Ginsenoside Rg1 inhibits platelet activation and arterial thrombosis. Thromb Res. 2014 Jan;133(1):57-65. PMID: 24196231.

Oh HA, Seo JY, Jeong HJ, et al. Ginsenoside Rg1 inhibits the TSLP production in allergic rhinitis mice. Immunopharmacol Immunotoxicol. 2013 Dec;35(6):678-86. PMID: 24053327.

Zhang YJ, Zhang XL, Li MH, et al. The ginsenoside Rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis. J Cardiovasc Pharmacol. 2013 Jul;62(1):50-7. PMID: 23846802.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • V0147

    Valproic Acid Sodium

    T-type Ca2+ and voltage-gated Na+ channel block...

    ≥98%
  • D0368

    2-Epi-16-deoxysarcophine

    Cembranoid found in Sarcophyton.

    ≥98%
  • F1607

    Febuxostat

    Xanthine oxidase inhibitor.

    ≥98%
  • P0346

    Palosuran Hydrochloride

    Urotensin II receptor antagonist.
  • S8253

    Sunitinib Malate

    Indoline; PDGFR, VEGFR, c-KIT, FLT3, mTORC1 inh...

    ≥98%
  • K0021

    K252a

    Staurosporine analog; PKC inhibitor, TrkA/B ant...

    ≥98%
  • P5885

    Povidone Iodine

    Polyvinyl pyrrolidone polymer, disinfectant.

    ≥98%
  • P2012

    PF-04217903

    Triazolopyrazine; c-MET inhibitor.

    ≥98%
  • A7208

    Ascomycin

    FK506 analog; calcineurin inhibitor.

    ≥98%
  • E4902

    Emamectin B1 Benzoate

    Semi-synthetic avermectin; GABA potentiator.

    ≥80%
  • N8662

    NVP-BGJ398

    FGFR inhibitor.

    ≥98%
  • D1629

    Dehydroepiandrosterone

    Endogenous steroid hormone; ERβ, NMDA, σ1 agonis...
    ≥98%
  • E4444

    Ellagic Acid

    Phenol found in various fruits; HDAC modulator....

    ≥98%
  • P3209

    Piceatannol

    Polyphenolic hydroxystilbene, resveratrol deri...

    ≥99%
  • C9670

    Cyromazine

    Triazine, melamine derivative, insect growth re...

    ≥98%
  • V1870

    Verruculogen

    Mycotoxin produced by Aspergillus; BK K+ channe...

    ≥95%
  • P6004

    PP-242

    Dual mTORC1/mTORC2 inhibitor.

    ≥98%
  • Q8139

    Quizartinib

    FLT3, c-Kit, PDGFR inhibitor.

    ≥98%
  • B3203

    Biapenem

    β-lactam; penicillin binding protein inhibitor...

    ≥98%
  • L960002

    LY-294002 Hydrochloride

    Inhibitor of PI3K.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only